Industry
Xenikos
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
Failure Rate
66.7%
2 terminated/withdrawn out of 3 trials
Success Rate
33.3%
-53.2% vs industry average
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed trials have results
Key Signals
2 with results
Enrollment Performance
Analytics
Phase 3
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 3(2)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT04934670Phase 3Terminated
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
Role: lead
NCT04128319Phase 3Terminated
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
Role: lead
NCT02027805Phase 1Completed
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
Role: lead
All 3 trials loaded